PYC Therapeutics Limited (PYC.AX)
| Previous close | 0.0940 |
| Open | 0.1000 |
| Bid | 0.1000 x 42340100 |
| Ask | 0.1100 x 21464600 |
| Day's range | 0.0930 - 0.1100 |
| 52-week range | 0.0500 - 0.1100 |
| Volume | |
| Avg. volume | 1,701,784 |
| Market cap | 410.616M |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.30 |
PR NewswirePYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].
Simply Wall St.Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
PR NewswireUS FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAM
PYC Therapeutics Limited (ASX:PYC) today announces that the VP-001 program, the first investigational drug candidate designed to address Retinitis Pigmentosa type 11 (RP11) to progress to human trials, has received Fast Track designation from the US Food and Drug Administration (FDA).
